Concise syntheses of the Cephalotaxus norditerpenoids
cephanolides A–D (8–14 steps from commercial material)
using a common late-stage synthetic intermediate are described. The
success of our approach rested on an early decision to apply chemical
network analysis to identify the strategic bonds that needed to be
forged, as well as the efficient construction of the carbon framework
through iterative Csp2–Csp3 cross-coupling,
followed by an intramolecular inverse-demand Diels–Alder cycloaddition.
Strategic late-stage oxidations facilitated access to all congeners
of the benzenoid cephanolides isolated to date.
Total synthesis of bottromycin A can be accomplished through a diastereoselective Mannich reaction of a chiral sulfinamide, mercury-mediated intermolecular amidination, and cyclization of a constrained tetracyclic peptide. Exploitation of this process allowed the synthesis of several novel bottromycin analogs. The antimicrobial activity of these analogs was evaluated in vitro against Gram-positive bacteria, such as methicillin resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococci (VRE). Structure-activity relationships were explored taking into consideration the unique three-dimensional structure of the compounds. Notably, one of the new analogs devoid of a methyl ester, which is known to lower the in vivo efficacy of bottromycin, exhibited antibacterial bioactivity comparable to that of vancomycin.
<p>Natural product total synthesis inspires strategy development in chemical synthesis. In the 1960s, Corey and coworkers demonstrated a visionary preparation of the terpenoid longifolene, using “strategic bond analysis” to craft a synthesis route. This approach proposes that efficient synthesis routes to bridged, polycyclic, structures should be formulated to introduce the bulk of the target’s topological complexity at a late stage. In subsequent decades, similar strategies have proved general for the syntheses of a wide variety of bridged, polycyclic molecules. Here, we demonstrate that an orthogonal strategy, which utilizes a topologically complex bicyclo[2.2.1] starting material accessed through a scaffold rearrangement of (<i>S</i>)-carvone, leads to a remarkably short synthesis of the longifolene-related terpenoid longiborneol. We also employ a variety of late-stage C–H functionalization tactics in divergent syntheses of many longiborneol congeners. Our strategy should prove effective for the preparation of other topologically complex natural products that contain the bicyclo[2.2.1] framework.</p>
This article describes the first total synthesis of luminamicin
using a strategy combining chemical degradation with synthesis. Chemical
degradation studies provided a sense of the inherent reactivity of
the natural product, and deconstruction of the molecule gave rise
to a key intermediate, which became the target for chemical synthesis.
The core structure of the southern part of luminamicin was constructed
by a 1,6-oxa-Michael reaction to form an oxa-bridged ring, followed
by coupling with a functionalized organolithium species. Modified
Shiina macrolactonization conditions forged the strained 10-membered
lactone containing a tri-substituted olefin. Diastereoselective α-oxidation
of the 10-membered lactone completed the center part to provide the
key intermediate. Inspired by the degradation study, an unprecedented
enol ether/maleic anhydride moiety was constructed with a one-pot
chlorosulfide coupling and thiol β-elimination sequence. Finally,
macrolactonization to the 14-membered ring in the presence of the
highly electrophilic maleic anhydride moiety was accomplished using
modified Mukaiyama reagents to complete the synthesis of luminamicin.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.